NeuRegen Biologics Secures Nearly RMB 100 Million in Series A Funding to Advance Pioneering In Vivo Transdifferentiation Therapies
NEUREGEN
Novel Gene Therapy Drug Developer
NEUREGEN Officially Announces Completion of Series A FinancingRecently, NEUREGEN officially announced the completion of its Series A financing round. The round was led by Wuhan Optics Valley Science and Technology Innovation Industry Investment Fund Partnership (Limited Partnership), with participation from Zhuhai Hengqin SoftBank Xinchuang Equity Investment Management Enterprise (Limited Partnership). Combined with the Pre-A+ round, which was completed through additional investments from existing shareholders, the company’s recent fundraising total has approached RMB 100 million. It is reported that the funds raised in this round will be primarily used to advance clinical trials for the company’s core drug pipeline, support preclinical research and development for other drug candidates, and continuously optimize its core technology platforms.
NEUREGEN is a biotechnology company focused on the research and development of innovative drugs in the field of cell and gene therapy (CGT). Its core technology relies on proprietary in situ transdifferentiation (i.e., in vivo cellular reprogramming) technology. This technology represents a next-generation cellular reprogramming approach iteratively developed from the Nobel Prize-winning induced pluripotent stem cell (iPSC) technology, and is regarded as a landmark breakthrough in the field of regenerative medicine. The company is committed to providing patients with novel therapeutic options by “precisely reprogramming cells within the diseased microenvironment in vivo.”
The company’s founding team comprises senior experts in neurobiology, oncology, ophthalmology, and the biopharmaceutical industry. Core members hail from prestigious academic and corporate institutions both in China and abroad, including the Chinese Academy of Sciences, Peking Union Medical College, the University of California, San Francisco (UCSF), the University of Florida, and UT Southwestern Medical Center. The team not only possesses cutting-edge international expertise and translational experience in in situ transdifferentiation technology but also has a proven track record of success across the entire drug development lifecycle. Leveraging this core technology, NEUREGEN has established a novel cell and gene therapy (CGT) drug development platform that covers key stages such as transdifferentiation factor screening, viral and non-viral vector design, and the development of in vitro and in vivo pharmacodynamic methodologies.
According to reports, NEUREGEN has established multiple innovative product pipelines around its original and globally leading technology platform, targeting major areas of unmet clinical needs such as oncology, ophthalmology, and neurodegenerative diseases. The first phase of its product development focuses on nervous system tumors and degenerative diseases, with particular emphasis on developing original drugs for blinding eye diseases, other degenerative conditions, and hard-to-treat nervous system tumors. In the future, the company plans to expand into broader fields, including the treatment of diseases affecting other tissues and organs, as well as anti-aging therapies.
Among these, NRG-103 injection, the core product targeting high-grade gliomas (glioblastoma), is a disruptive innovative therapy independently developed by NEUREGEN. Leveraging its unique dual mechanism of action, this product has achieved breakthroughs in addressing the extreme biological complexity and treatment limitations of the disease: on one hand, it utilizes next-generation oncolytic viruses to selectively and precisely kill tumor cells; on the other hand, it employs in situ transdifferentiation technology to convert residual or escaped tumor cells post-surgery into non-tumor cells that no longer proliferate, thereby curbing tumor recurrence and drug-resistant escape at the source. With this cutting-edge technology platform and product design, NRG-103 was awarded the Grand Prize Winner at the 2024 National Disruptive Technology Innovation Competition organized by the Ministry of Science and Technology of China. Currently, the product has successively obtained clinical trial approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, as well as Orphan Drug Designation (ODD) and Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). It has now officially entered Phase I clinical trials for registration in China.
The rapid development of NEUREGEN is a microcosm of the current booming growth of China’s cell and gene therapy (CGT) industry. As the third-generation revolutionary therapy following small molecules and antibody drugs, CGT is accelerating its transition from the laboratory to clinical application, becoming one of the most dynamic sectors in the biopharmaceutical field. With continuous breakthroughs in regulatory policies, supply chain infrastructure, and core technologies in China, the Chinese CGT industry is gradually shifting from “following” to “running alongside,” and even “leading.” In the future, as more innovative enterprises like NEUREGEN continue to drive technological iteration and the translation of scientific achievements into practical applications, CGT therapies are expected to make substantial progress in addressing major clinical challenges such as cancer, rare diseases, and degenerative disorders. This will truly enable a shift from “high-cost, limited-access” treatments to “affordable and widely accessible” solutions, bringing new hope for cures to patients worldwide.
E.N.D
Declaration:ReferenceInternalCapacityComeSourced from official media/online news, this publicOfficial AccountAimed atKnowledge sharing; maintain neutrality regarding the content, statements, and opinions in reposts or shares, without endorsing their accuracyNo express or implied warranties are made regarding the accuracy, reliability, or completeness of the content, which is provided for readers' reference only.